In the tumor at those doses which markedly prolonged survival (Ad-RTS-mIL-12+veledimex 10 and 30 mg/m2/day), we observed sustained increase in tumor cytotoxic T cells (CD3+CD8+) concomitant with sustained reductions in T regulatory cells (Fig. 3). This evidence concerns the gene CD8A and neoplasm.